<SEC-DOCUMENT>0001193125-21-322598.txt : 20211108
<SEC-HEADER>0001193125-21-322598.hdr.sgml : 20211108
<ACCEPTANCE-DATETIME>20211108113133
ACCESSION NUMBER:		0001193125-21-322598
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20211108
FILED AS OF DATE:		20211108
DATE AS OF CHANGE:		20211108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		211387007

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d252088d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2021. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-40673</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Cybin Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name
of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>100 King
Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> Form&nbsp;20-F&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9746;</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule
101(b)(1) only permits the submission in paper of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> if submitted solely to provide an attached annual report to security holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule
101(b)(7) only permits the submission in paper of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> submission or other Commission filing on EDGAR. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>CYBIN INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;8, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Doug Drysdale</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Doug Drysdale</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT INDEX </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d252088dex991.htm">News Release dated November&nbsp;8, 2021</A></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d252088dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g252088g1108000240978.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cybin Announces Positive CYB003 Data Demonstrating Significant </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Advantages Over Oral Psilocybin for Treatment of Mental Health </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Comparative CYB003 <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data on the Company&#146;s deuterated psilocybin analog may have
wide-reaching implications for the treatment of Major Depressive Disorder (&#147;<B>MDD</B>&#148;) and Alcohol Use Disorder (&#147;<B>AUD</B>&#148;) with less patient variability, faster onset of action, shorter duration of effect and improved brain
penetration </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TORONTO, CANADA </B>&#150; November&nbsp;8, 2021 &#150; <U>Cybin</U><U> Inc.</U> (<U>NEO:CYBN</U>) (<U>NYSE American:CYBN</U>)
(&#147;<B>Cybin</B>&#148; or the &#147;<B>Company</B>&#148;), a biopharmaceutical company focused on progressing &#147;Psychedelics to Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>&#148;, today announced positive CYB003 <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> findings that demonstrate multiple advantages for its newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare, but few companies have addressed the
well-known limitations and side effects of oral psilocybin. Cybin has always strived to develop safer and more effective therapies for patients, which has guided our multiple psilocybin programs: CYB001, CYB002, and CYB003,&#148; said Doug Drysdale,
Cybin&#146;s Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Academic research performed at New York University and John Hopkins University has indicated oral psilocybin to be
efficacious in the treatment of mental health disorders, especially MDD, but with significant limitations, specifically: slow onset of action, extended duration of effect, and a variability in response among patients. The Company&#146;s CYB001 and
CYB002 programs studied proprietary formulations, while the Company&#146;s CYB003 program explored proprietary analogs with the goal to retain the benefits and address the challenges. Today the Company is pleased to announce that its proprietary
molecular advancements offer positive benefits and address the challenges and limitations of oral psilocybin. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In multi-species <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, the Company&#146;s deuterated
psilocybin analog from its CYB003 program demonstrates: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a 50% reduction in variability compared to oral psilocybin; indicates potential for more accurate dosing in
patients with MDD and AUD; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a 50% reduction in dose compared to oral psilocybin; indicates potential to maintain equivalent efficacy while
reducing side effects, such as nausea, in patients with MDD and AUD; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a 50% shorter time to onset when compared to oral psilocybin; indicates potential for shorter duration of
treatment, lower inter-subject variability, better therapeutic control and safety, leading to a better patient experience, with lower cost and scalability; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">nearly double brain penetration when compared to oral psilocybin; indicates potential for a less variable
treatment response, a lower dose therapeutic effect, and reduced patient side effects. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The deuterated psilocybin analog in CYB003 has
the potential to reduce time and resource burden on patients,&nbsp;providers and payers, and possibly improving scalability and accessibility from the following conclusions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">faster onset of action equates to less down time in the clinic before effects begin; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">half the duration of effect translates to shorter clinic days or more patients per day; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">more predictable dose effects create a safer and more effective patient response; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lowered peripheral exposure diminishes the risk of nausea; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">better brain penetration suggests lower overall dose needed to achieve clinical efficacy. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;While we are all encouraged by the benefits of psilocybin, we need to transparently and openly discuss its limitations if we are to translate
psychedelics to therapeutics for patients in need. The majority of current clinical studies are based on psilocybin. We have taken the necessary steps to potentially unlock the powerful benefits of psychedelics and engineer a superior molecule as
demonstrated by the data. We are on a mission to make ethical, safe scientific progress to advance the care and treatment of mental health patients. Our goal has always been to be a leader in creating the best therapy for patients, today we move one
step closer,&#148; said Doug Drysdale, Cybin&#146;s Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The presentation showcasing the Company&#146;s data will be made available
on the Cybin website within 24 hours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a reminder, the Company welcomes all media and analysts that are attending the Wonderland Conference in Miami to
physically join its presentation today at 8:30am EDT. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Physical address for attendees: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Physical event is for media attendees and analysts only. To RSVP, please email <U>info@cybin.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Adrienne Arsht Center for the Performing Arts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Next
Generation Green Room </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arts of Miami-Dade County, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1300
Biscayne Blvd. Miami, FL 33132 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company welcomes shareholders and the general public to virtually join its presentation today at 8:30am EDT. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Virtual Webcast: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Virtual event is open to shareholders
and the general public. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topic: Cybin Research&nbsp;&amp; Development Press Conference </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Location: Wonderland Conference, Miami, FL </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Time: Nov 8, 2021
08:30 AM Eastern Time (US and Canada) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Join Zoom Meeting </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://imageav.zoom.us/j/82993672583?pwd=cW9zQi9Xc1BCbExpTGh5T09aS1hGUT09</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One tap mobile </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+13462487799,,82993672583#,,,,*730988# US </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dial by your location </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Meeting ID: 829 9367 2583 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Passcode: 730988 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Find your local number:
<U>https://imageav.zoom.us/u/kWOoByjaK</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cybin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally-recognized scientists, on a mission to
create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the USA, UK and Ireland. The Company is focused on progressing Psychedelics to
Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Notes and Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this
press release, including, without limitation, statements regarding Cybin&#146;s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words &#147;believe&#148;, &#147;expect&#148;,
&#147;aim&#148;, &#147;intend&#148;, &#147;plan&#148;, &#147;continue&#148;, &#147;will&#148;, &#147;may&#148;, &#147;would&#148;, &#147;anticipate&#148;, &#147;estimate&#148;, &#147;forecast&#148;, &#147;predict&#148;, &#147;project&#148;,
&#147;seek&#148;, &#147;should&#148; or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the potential benefits of the Company&#146;s multiple
psilocybin program CYB001, CYB002, and CYB003, the potential benefits of psilocybin, and the development of the Company&#146;s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment
regimens in order to advance the care and treatment of mental health patients and to address a multitude of mental health issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking
statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks,
uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such
factors, among other things, include: implications of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations
regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations
that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company&#146;s management&#146;s discussion and analysis for the period ended June&nbsp;30, 2021 and the Company&#146;s listing statement
dated November&nbsp;9, 2020, which are available under the Company&#146;s profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release
are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other
factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the
forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybin makes no medical,
treatment or health benefit claims about Cybin&#146;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine
derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products.
Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to
commercialize its business, it may have a material adverse effect on Cybin&#146;s performance and operations. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the
contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media
Contacts:</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leah Gibson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President Investor Relations
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybin Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>leah@cybin.com </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim Regan/Scott Eckstein </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KCSA Strategic Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>cybin@kcsa.com</U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lisa M. Wilson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-Site</FONT> Communications, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lwilson@insitecony.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g252088g1108000240978.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g252088g1108000240978.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #2 2,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYQ@Y)KTBKJTI4Y<LMQ)IJZ"BBBLQA1110 4444 %%%% !1110 4444 %%%%
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M'GUGPK]KMT+7.GMYP ZE,?,/RY_"OGP'H0?<&O=P<U.BEVT.:HK2/L"BN?\
M!>OP>(O#%G=QR*TRH(YUSRK@8.?KU_&N@KQ)1<9.+Z'0G=7"BHKFY@L[=Y[F
M:.&%!EGD8* /J:\D\8_%Y2LECX:Y)^5KYEX'^X#U^IJZ5"=5VBA2DH[G6>-_
MB%8^%(&MH=MSJCK\D /"?[3^@]N]<)\-;GQ#XD\;R:K<W]R]O"I,^7/EG/1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
